Literature DB >> 19470628

High prevalence of impaired glucose homeostasis and myopathy in asymptomatic and oligosymptomatic 3243A>G mitochondrial DNA mutation-positive subjects.

Anja Lisbeth Frederiksen1, Tina Dysgaard Jeppesen, John Vissing, Marianne Schwartz, Kirsten Ohm Kyvik, Ole Schmitz, Per Løgstrup Poulsen, Per Heden Andersen.   

Abstract

INTRODUCTION: The point mutation of 3243A>G mtDNA is the most frequent cause of mitochondrial diabetes, often presenting as the syndrome maternally inherited diabetes and deafness (MIDD). The mutation may also cause myopathy, ataxia, strokes, ophthalmoplegia, epilepsy, and cardiomyopathy in various combinations. Consequently, it is difficult to predict the "phenotypic risk profile" of 3243A>G mutation-positive subjects. The 3243A>G mutation coexists in cells with wild-type mtDNA, a phenomenon called heteroplasmy. The marked variability in mutation loads in different tissues is the main explanation for the different phenotypes associated with this mutation. AIM: The aim of the study was to screen asymptomatic and oligosymptomatic 3243A>G mtDNA carriers for diabetes and myopathy.
METHODS: The study is a case-control study. Nineteen adult 3243A>G carriers presumed to be normoglycemic and matched healthy controls were subjected to an oral glucose tolerance test. Twenty-six adult 3243A>G carriers with unknown myopathy status and 17 healthy controls had a maximal cycle test and a muscle biopsy performed. The mutation loads were quantified in blood and muscle biopsies and correlated to the clinical manifestations of the mutation.
RESULTS: In the presumed normoglycemic 3243A>G-positive subjects, one subject had overt diabetes, and 10 subjects had impaired glucose tolerance. Sixteen of the 26 subjects with unknown oxidative capacity fulfilled criteria for myopathy. The mutation load in blood and muscle correlated with the age for diagnosis of impaired glucose homeostasis and hearing impairment (rho = -0.71 to -0.78; P < 0.0001).
CONCLUSION: The findings suggest that 3243A>G mutation carriers should be screened for diabetes and myopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470628     DOI: 10.1210/jc.2009-0235

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Myocardial glucose uptake in patients with the m.3243A > G mutation in mitochondrial DNA.

Authors:  Markus M Lindroos; Jussi P Pärkkä; Markku T Taittonen; Patricia Iozzo; Mikko Kärppä; Ilmo E Hassinen; Juhani Knuuti; Pirjo Nuutila; Kari Majamaa
Journal:  J Inherit Metab Dis       Date:  2015-06-26       Impact factor: 4.982

2.  Glucose metabolism derangements in adults with the MELAS m.3243A>G mutation.

Authors:  Ayman W El-Hattab; Lisa T Emrick; Jean W Hsu; Sirisak Chanprasert; Farook Jahoor; Fernando Scaglia; William J Craigen
Journal:  Mitochondrion       Date:  2014-07-30       Impact factor: 4.160

Review 3.  Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes.

Authors:  Roseanne O Yeung; Fady Hannah-Shmouni; Karen Niederhoffer; Mark A Walker
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

4.  Mitochondrial DNA variants in the pathogenesis of type 2 diabetes - relevance of asian population studies.

Authors:  Pei-Wen Wang; Tsu-Kung Lin; Shao-Wen Weng; Chia-Wei Liou
Journal:  Rev Diabet Stud       Date:  2009-12-30

5.  Mitochondrial mutation m.3243A>G associates with insulin resistance in non-diabetic carriers.

Authors:  Jakob Høgild Langdahl; Anja Lisbeth Frederiksen; John Vissing; Morten Frost; Knud Bonnet Yderstræde; Per Heden Andersen
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

Review 6.  Humanin and diabetes mellitus: A review of in vitro and in vivo studies.

Authors:  Chrysoula Boutari; Panagiotis D Pappas; Theodoros D Theodoridis; Dimitrios Vavilis
Journal:  World J Diabetes       Date:  2022-03-15

7.  Humanin: a novel central regulator of peripheral insulin action.

Authors:  Radhika H Muzumdar; Derek M Huffman; Gil Atzmon; Christoph Buettner; Laura J Cobb; Sigal Fishman; Temuri Budagov; Lingguang Cui; Francine H Einstein; Aruna Poduval; David Hwang; Nir Barzilai; Pinchas Cohen
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

8.  Management of mitochondrial diabetes in the era of novel therapies.

Authors:  Roseanne O Yeung; Mohammad Al Jundi; Sriram Gubbi; Maria E Bompu; Sandra Sirrs; Mark Tarnopolsky; Fady Hannah-Shmouni
Journal:  J Diabetes Complications       Date:  2020-04-13       Impact factor: 2.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.